CO6220836A2 - Compuestos activos biologicamnete marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo2,5-dioxo-pirrolidin-1-iloxi-benzoilo y trimetilamonio benzoilo - Google Patents
Compuestos activos biologicamnete marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo2,5-dioxo-pirrolidin-1-iloxi-benzoilo y trimetilamonio benzoiloInfo
- Publication number
- CO6220836A2 CO6220836A2 CO09092675A CO09092675A CO6220836A2 CO 6220836 A2 CO6220836 A2 CO 6220836A2 CO 09092675 A CO09092675 A CO 09092675A CO 09092675 A CO09092675 A CO 09092675A CO 6220836 A2 CO6220836 A2 CO 6220836A2
- Authority
- CO
- Colombia
- Prior art keywords
- benzoilo
- group
- iloxi
- substituent
- so2r5
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/086—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nuclear Medicine (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
1.- Un compuesto que tiene una fórmula química general (A):en el cual uno de -Y1, -Y2, -Y3, -Y4 e -Y5 es un primer sustituyente (-G) que se seleccione del grupo que comprende -H, -f, -Cl, -Br, -I, -NO, -NO2, -NR4COCF3, -NR4SO2CF3, -N(CF3)2, -NHCSNHR4, -N(SO2R5)2, -N(O)=NCONH2, NR4CN, -NHCSR5, -N=C, -N=C(CF3)2, -N=NCF3, -N=NCN, -NR4COR4, -NR4COOR5, -OSO2CF3, -OSO2C6H5, -OCOR5, -ONO2, -OSO2R5, -O-C=CH2, -OCF2CF3, -OCOCF3, -OCN, -OCF3, -C=N, -C(NO2)3, -COOR4, -CONR4R5, -C(S)NH2, -CH=NOR4, -CH2SO2R4, -COCF3, -CF3, -CF2Cl-CBr3, -CClF2, -CCl3, -CF2CF3, -C=CR4, -CH=NSO2CF3, -CH2CF3, -COR5, -CH=NOR5, -CH2CONH2, -CSNHR5, -CH=NNHCSNH2, -CH=NNHCONHNH2, -C=C-CF3, -CF=CFCF3, -CF2-CF2- -CF3, -CR4(CN)2, -COCF2CF2CF3, -C(CF3)3, -C(CN)3, -CR4=C(CN)2, -1-pirrilo, -C(CN)=C(CN)2, -C-piridilo, -COC6H5, -COOC6H5, -SOCF3, -SO2CF3, -SCF3, -SO2CN, -SCOCF3, -SOR5, -S(OR5), -SC=CR4, -SO2R5, -SSO2R5, -SR5, -SSR4, -SO2CF2CF3, -SCF2CF3, -S(CF3)=NSO2CF3, -SO2C6H5, -SO2N(R5)2, -SO2C(CF3)3, -SO(CF3)3, -SO(CF3)=NSO2CF3, -S(O)(=NH)CF3, -S(O)(=NH)R5, -S-C=CH2, -SCOR5, -SOC6H5, -P(O)C3F7, -PO(OR5)2, -PO(N(R5)2)2, -P(N(R5)2)2, -P(O)R52 y -PO(OR5)2, y grupos sustractores de electrones, donde el sustituyente respectivo puede estar en posición orto, para o meta respecto del grupo K (LG-O); al menos uno de -Y1, -Y2, -Y3, -Y4 e -Y5 es un sustituyente adicional (-Q) que se selecciona independientemente del grupo que comprende -H, -CN, -halógeno, -CF3, -NO2, -COR5 y -SO2R5, donde el sustituyente respectivo puede estar en posición orto, para o meta respecto del grupo K (LG-O), donde R4 es hidrógeno o un C1-C6 alquilo lineal o ramificado, R5 es hidrógeno o un C1-C6 alquilo lineal o ramificado, donde además, uno de -Y1, -Y2, -Y3, -Y4 e -Y5 es -A-B-D-P, donde -A-B-D- es un enlace o un separador, P es un agente de direccionamiento, y K es LG-O o W, donde: LG es un grupo saliente, que puede desplazarse con una reacción de sustitución nucleofílica aromática, y W es un isótopo de flúor (F), y también cualquier sal o ácido orgánico o inorgánico, hidrato, éster, amida, solvato y prodrogas de éste aceptable para el uso farmacéutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07090035A EP1964848A1 (en) | 2007-03-01 | 2007-03-01 | Radiofluorination methods |
EP07090079A EP1985624A3 (en) | 2007-04-23 | 2007-04-23 | Single step method of radiofluorination of biologically active compounds or biomolecules |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6220836A2 true CO6220836A2 (es) | 2010-11-19 |
Family
ID=39522200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09092675A CO6220836A2 (es) | 2007-03-01 | 2009-09-01 | Compuestos activos biologicamnete marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo2,5-dioxo-pirrolidin-1-iloxi-benzoilo y trimetilamonio benzoilo |
Country Status (22)
Country | Link |
---|---|
US (1) | US20090317326A1 (es) |
EP (1) | EP2146753A2 (es) |
JP (1) | JP2010520229A (es) |
KR (1) | KR20090119966A (es) |
AR (1) | AR062796A1 (es) |
AU (1) | AU2007348145A1 (es) |
BR (1) | BRPI0721424A2 (es) |
CA (1) | CA2679514A1 (es) |
CL (1) | CL2007002672A1 (es) |
CO (1) | CO6220836A2 (es) |
CR (1) | CR11011A (es) |
DO (1) | DOP2009000210A (es) |
EA (1) | EA200901142A1 (es) |
EC (1) | ECSP099610A (es) |
IL (1) | IL200034A0 (es) |
MX (1) | MX2009009291A (es) |
PA (1) | PA8747701A1 (es) |
PE (1) | PE20081355A1 (es) |
SV (1) | SV2009003364A (es) |
TW (1) | TW200836764A (es) |
UY (1) | UY30595A1 (es) |
WO (1) | WO2008104203A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
AU2009225407B2 (en) | 2008-03-21 | 2013-09-05 | The General Hospital Corporation | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders |
US20100129290A1 (en) * | 2008-11-26 | 2010-05-27 | I.S.T. Corporation | Smart contrast agent and detection method for detecting transition metal ions |
US20100227794A1 (en) * | 2008-11-26 | 2010-09-09 | I.S.T. Corporation | Smart contrast agent and method for detecting transition metal ions and treating related disorders |
GB201013808D0 (en) | 2010-08-18 | 2010-09-29 | Ge Healthcare Ltd | Peptide radiotracer compositions |
KR101478140B1 (ko) * | 2011-05-13 | 2014-12-31 | (주)퓨쳐켐 | 18f-표지 pet 방사성의약품의 전구체 및 그 제조방법 |
AU2012267998A1 (en) * | 2011-06-09 | 2014-01-09 | Ge Healthcare Limited | Distillation device and method |
EP2540710A1 (en) | 2011-06-30 | 2013-01-02 | Bayer Schering Pharma Aktiengesellschaft | New precursors for direct radiosynthesis of protected derivatives of O-([18F]Fluoromethyl) tyrosine |
US20140309424A1 (en) | 2011-06-30 | 2014-10-16 | Piramal Imaging Sa | Direct synthesis of 18f-fluoromethoxy compounds for pet imaging and the provision of new precursors for direct radiosynthesis of protected derivatives of o-([18f] fluoromethyl) tyrosine |
GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723578A (en) * | 1987-09-24 | 1998-03-03 | The Administrators Of Tulane Educational Fund | Peptide analogs of bombesin |
US5084555A (en) * | 1989-08-21 | 1992-01-28 | The Administrators Of The Tulane Educational Fund | An octapeptide bombesin analog |
US6083915A (en) * | 1991-05-10 | 2000-07-04 | Biomeasure, Inc. | Method for treating liver cancer |
TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
US6639076B1 (en) * | 1998-08-18 | 2003-10-28 | Eli Lilly And Company | Growth hormone secretagogues |
DE60022508T2 (de) * | 1999-06-14 | 2006-06-08 | Eli Lilly And Co., Indianapolis | Inhibitoren von serin proteasen |
HUP0400758A3 (en) * | 2000-11-03 | 2005-02-28 | Bristol Myers Squibb Pharma Co | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation |
US7115766B2 (en) * | 2000-11-30 | 2006-10-03 | Indiana University Research & Technology Corp. | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds |
TWI311133B (en) * | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
CA2516685A1 (en) * | 2003-02-20 | 2004-09-02 | University Of South Florida | Peptidomimetic inhibitors of stat3 activity and their medical uses |
GB0305704D0 (en) * | 2003-03-13 | 2003-04-16 | Amersham Plc | Radiofluorination methods |
WO2005002293A2 (en) * | 2003-06-25 | 2005-01-06 | Vanderbilt University | Cox-2-targeted imaging agents |
GB0420344D0 (en) * | 2004-09-14 | 2004-10-13 | Amersham Plc | Diagnostic compounds |
JP2008515876A (ja) * | 2004-10-07 | 2008-05-15 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | イメージング及び治療用のイメージング及び治療のエンドキットにおけるシュタウディンガーライゲーションの使用 |
WO2006083424A2 (en) * | 2004-12-28 | 2006-08-10 | The Trustees Of Columbia University In The City Of New York | Radiolabeled compounds and uses thereof |
WO2006074799A2 (en) * | 2005-01-17 | 2006-07-20 | Universitätsklinikum Münster | 5-pyrrolidinylsulfonyl isatin derivatives |
KR20090058553A (ko) * | 2006-09-08 | 2009-06-09 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 18f 표지된 작용제에 대한 화합물 및 방법 |
-
2007
- 2007-09-07 AU AU2007348145A patent/AU2007348145A1/en not_active Abandoned
- 2007-09-07 BR BRPI0721424-3A patent/BRPI0721424A2/pt not_active IP Right Cessation
- 2007-09-07 JP JP2009551918A patent/JP2010520229A/ja active Pending
- 2007-09-07 KR KR1020097018125A patent/KR20090119966A/ko not_active Application Discontinuation
- 2007-09-07 EP EP07802293A patent/EP2146753A2/en not_active Withdrawn
- 2007-09-07 EA EA200901142A patent/EA200901142A1/ru unknown
- 2007-09-07 WO PCT/EP2007/007967 patent/WO2008104203A2/en active Application Filing
- 2007-09-07 MX MX2009009291A patent/MX2009009291A/es not_active Application Discontinuation
- 2007-09-07 US US11/851,940 patent/US20090317326A1/en not_active Abandoned
- 2007-09-07 CA CA002679514A patent/CA2679514A1/en not_active Abandoned
- 2007-09-10 TW TW096133847A patent/TW200836764A/zh unknown
- 2007-09-14 PA PA20078747701A patent/PA8747701A1/es unknown
- 2007-09-14 AR ARP070104088A patent/AR062796A1/es unknown
- 2007-09-14 PE PE2007001248A patent/PE20081355A1/es not_active Application Discontinuation
- 2007-09-14 UY UY30595A patent/UY30595A1/es not_active Application Discontinuation
- 2007-09-14 CL CL200702672A patent/CL2007002672A1/es unknown
-
2009
- 2009-07-23 IL IL200034A patent/IL200034A0/en unknown
- 2009-09-01 SV SV2009003364A patent/SV2009003364A/es not_active Application Discontinuation
- 2009-09-01 CR CR11011A patent/CR11011A/es unknown
- 2009-09-01 DO DO2009000210A patent/DOP2009000210A/es unknown
- 2009-09-01 CO CO09092675A patent/CO6220836A2/es not_active Application Discontinuation
- 2009-09-01 EC EC2009009610A patent/ECSP099610A/es unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2009000210A (es) | 2010-08-31 |
SV2009003364A (es) | 2010-01-27 |
CL2007002672A1 (es) | 2008-09-12 |
JP2010520229A (ja) | 2010-06-10 |
TW200836764A (en) | 2008-09-16 |
EA200901142A1 (ru) | 2010-04-30 |
AR062796A1 (es) | 2008-12-03 |
ECSP099610A (es) | 2009-10-30 |
CA2679514A1 (en) | 2008-09-04 |
UY30595A1 (es) | 2008-09-30 |
BRPI0721424A2 (pt) | 2014-03-25 |
US20090317326A1 (en) | 2009-12-24 |
EP2146753A2 (en) | 2010-01-27 |
AU2007348145A1 (en) | 2008-09-04 |
KR20090119966A (ko) | 2009-11-23 |
CR11011A (es) | 2009-10-19 |
MX2009009291A (es) | 2009-12-14 |
IL200034A0 (en) | 2010-04-15 |
WO2008104203A3 (en) | 2009-02-05 |
PE20081355A1 (es) | 2008-12-05 |
PA8747701A1 (es) | 2009-08-26 |
WO2008104203A2 (en) | 2008-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6220836A2 (es) | Compuestos activos biologicamnete marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo2,5-dioxo-pirrolidin-1-iloxi-benzoilo y trimetilamonio benzoilo | |
CO6150196A2 (es) | Agentes que comprenden compuestos marcados con 18f y metodos relacionados | |
US10738001B2 (en) | Hydrofluoroolefins and methods of using same | |
JP2021042387A (ja) | 塗膜形成用組成物および塗膜の形成方法 | |
EP3303436B1 (en) | Hydrofluoroolefins and methods of using same | |
BR112013006255B1 (pt) | composição à base de ferroceno para extinguir fogo | |
KR20190142405A (ko) | 에어로졸 세정 조성물 | |
BR112014012847A2 (pt) | composição fluoroquímica e uso desta | |
AR105927A1 (es) | Compuesto para usar en composiciones que cambian de color | |
JP7043489B2 (ja) | 窒素及び/又は酸素含有ヒドロフルオロオレフィン、並びにその製造方法及び使用方法 | |
KR20190040979A (ko) | 프로페닐아민 및 이의 제조 및 사용 방법 | |
CN102076649A (zh) | 氢氟缩醛化合物以及它们的制备和使用方法 | |
BRPI0800167A (pt) | composição aquosa, e, processos para fornecer uma composição aquosa, e um revestimento polimérico | |
Tale et al. | A practical and general ipso iodination of arylboronic acids using N-iodomorpholinium iodide (NIMI) as a novel iodinating agent: mild and regioselective synthesis of aryliodides | |
EP2818536B1 (en) | Oil additive for fluorinated oils | |
MY154066A (en) | 1,2,4,-triazin-3,5-dione compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor | |
FR2933691B1 (fr) | Hydro(chloro)fluoroolefines et leur procede de preparation | |
CN103450781A (zh) | 耐烃类室内薄涂型钢结构防火涂料 | |
WO2012169757A3 (ko) | 열 기계장치 및 급수 배관 내부의 스케일 제거 및 방청용 화합물 및 이를 함유한 조성물 | |
FR2567140A1 (fr) | Application de melanges stables d'hydrocarbures chlorofluores et de solvants a titre de composition calogene pour pompe a chaleur a absorption | |
C. Regan et al. | Structure and reactivity in the hydrolyses of aliphatic carboxylic acid esters and chlorides | |
JP2009161706A (ja) | グリース組成物 | |
FR2970880B1 (fr) | Agents moussants phosphores stables a haute temperature | |
WO2012176518A1 (ja) | 汚れ及び腐食の抑制方法及び抑制剤 | |
TH98407B (th) | การเตรียมสารต้านการออกซิเดชันชนิดฟีโนลิกในรูปแบบของไหล |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |